COGNITION THERAPEUTICS

Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease

05 июл 2023 06:30:06 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease

28 июн 2023 06:00:00 Источник Nasdaq GlobeNewswire

Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023

27 июн 2023 18:17:07 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches

20 июн 2023 06:30:15 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders Conferences

02 июн 2023 06:30:16 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC

23 май 2023 06:30:00 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease

18 май 2023 06:30:46 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

04 май 2023 15:05:54 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer

01 май 2023 06:30:44 Источник Nasdaq GlobeNewswire

Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023

19 апр 2023 06:30:52 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases

12 апр 2023 06:30:30 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer’s Disease Processes

28 мар 2023 06:30:40 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Announces New Episode of “Conversations” Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies

27 мар 2023 07:00:01 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update

23 мар 2023 06:30:00 Источник Nasdaq GlobeNewswire

Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023

21 мар 2023 07:00:32 Источник Nasdaq GlobeNewswire

UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results

16 мар 2023 11:18:55 Источник Nasdaq GlobeNewswire

Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results

16 мар 2023 06:30:53 Источник Nasdaq GlobeNewswire

Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD

15 мар 2023 06:30:16 Источник Nasdaq GlobeNewswire

Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference

07 мар 2023 07:00:13 Источник Nasdaq GlobeNewswire

Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease

22 фев 2023 07:00:02 Источник Nasdaq GlobeNewswire